Success and failure of vaccines against renin–angiotensin system components

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Nature Reviews Cardiology

• Publication date

  2009-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrcardio.2009.156PMID 19707182
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Continued Improvement in Hypertension Management in England: Results From the Health Survey for England 2006

  2009cited by this paper
• Telmisartan, ramipril, or both in patients at high risk for vascular events.

  2008cited by this paper
• Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study.

  2008cited by this paper
• The coming of age of virus-like particle vaccines

  2008cited by this paper
• Aliskiren.

  2008cited by this paper
• Thrombolytics for PE and right ventricular dysfunction.

  2008cited by this paper
• Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

  2008cited by this paper
• Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.

  2008cited by this paper
• The salt conundrum: a hypothesis.

  2007cited by this paper
• Essential hypertension.

  2007cited by this paper
• Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension

  2007cited by this paper
• Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system

  2007cited by this paper
• A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity

  2007cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

  2007cited by this paper
• Renin: friend or foe?

  2007cited by this paper
• Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data.

  2006cited by this paper
• Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults.

  2006cited by this paper
• Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.

  2005cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

  2005cited by this paper
• Global burden of hypertension: analysis of worldwide data.

  2005cited by this paper
• Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials

  2005cited by this paper
• Persistence with treatment in newly treated middle-aged patients with essential hypertension.

  2005cited by this paper
• Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri

  2005cited by this paper
• Renin-angiotensin vaccine: old story, new project 'efficacy versus safety'.

  2004cited by this paper
• Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

  2004cited by this paper
• Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man.

  2003cited by this paper
• Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003

  2003cited by this paper
• Better blood pressure control: how to combine drugs

  2003cited by this paper
• Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.

  2003cited by this paper
• Virus-Like Particles as a Modular System for Novel Vaccines

  2003cited by this paper
• Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects.

  2003cited by this paper
• Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

  2002cited by this paper
• Hyperaldosteronism Among Black and White Subjects With Resistant Hypertension

  2002cited by this paper
• Systolic and diastolic blood pressure control in antihypertensive drug trials.

  2002cited by this paper
• Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

  2002cited by this paper
• Effects of Valsartan on Mechanical Properties of the Carotid Artery in Spontaneously Hypertensive Rats Under High-Salt Diet

  2001cited by this paper
• Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)

  2000cited by this paper
• Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats

  2000cited by this paper
• Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

  2000cited by this paper
• Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.

  1999cited by this paper
• Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay

  1999cited by this paper
• Success of Surgery for Primary Aldosteronism Judged by Residual Autonomous Aldosterone Production

  1998cited by this paper
• Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

  1998cited by this paper
• Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor captopril.

  1993cited by this paper
• Brief Angiotensin Converting Enzyme Inhibitor Treatment in Young Spontaneously Hypertensive Rats Reduces Blood Pressure Long‐term

  1990cited by this paper
• Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin.

  1990cited by this paper
• Determinants of angiotensin II generation during converting enzyme inhibition.

  1990cited by this paper
• Immunologic approaches to blockade of the renin-angiotensin system: a review.

  1989cited by this paper
• Active immunization against renin in normotensive marmoset.

  1987cited by this paper
• Role of Angiotensinogen in Blood Pressure Homeostasis

  1982cited by this paper
• Pulmonary angiotensin-converting enzyme. Interspecies homology and inhibition by heterologous antibody in vivo.

  1976cited by this paper
• Active and Passive Immunization Against Angiotensin II in the Rat and Rabbit: EVIDENCE FOR A NORMAL REGULATION OF THE RENIN-ANGIOTENSIN SYSTEM

  1975cited by this paper
• Comparison of Angiotensin II Antagonist and Antiserum Infusion with Nephrectomy in the Rat with Two‐Kidney Goldblatt Hypertension

  1974cited by this paper
• Hypertension of Renal Origin: Evidence for Two Different Mechanisms

  1971cited by this paper
• Studies on the role of angiotensin in experimental renovascular hypertension: an immunologic approach.

  1969cited by this paper
• Antirenin in man and animals.

  1951cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Emerging therapeutic frontiers in hypertension management

  2025cites this paper
• Targeting aging and age-related diseases with vaccines

  2024cites this paper
• Combined vaccines against angiotensin II receptor type 1 and alpha 1D-adrenergic receptor for hypertension

  2024cites this paper
• Future treatments in hypertension: Can we meet the unmet needs of patients?

  2023cites this paper
• Computational mining of MHC class II epitopes for the development of universal immunogenic proteins

  2022cites this paper
• Modulating the immune response to reduce hypertension-associated cardiovascular damage

  2022cites this paper
• Clinical study on angiotensin II vaccination—the first big step

  2021cites this paper
• [New perspectives in the management of arterial hypertension].

  2021cites this paper
• Vaccines against components of the renin–angiotensin system

  2020cites this paper
• New Molecules for Treating Resistant Hypertension: a Clinical Perspective

  2019cites this paper
• Renin inhibition by soyasaponin I: a potent native anti-hypertensive compound

  2018cites this paper
• Gene therapy for hypertension

  2017cites this paper
• Interventional procedures and future drug therapy for hypertension

  2016cites this paper
• Recent advancements in combination subunit vaccine development

  2016cites this paper
• Current Approaches to Hypertension Treatment: Are there Promising Results?

  2015cites this paper
• New approaches in the treatment of hypertension.

  2015cites this paper
• A Short Review of Some Medicinal Plants And Phytocompounds With Hypotensive And Hypoglycemic Activities

  2014cites this paper
• Antibodies in the Pathogenesis of Hypertension

  2014cites this paper
• Effects of Angiotensin-Converting Enzyme Inhibitory Peptide LAP on Vascular Remodeling

  2013cites this paper
• Therapeutic Vaccines against Human and Rat Renin in Spontaneously Hypertensive Rats

  2013cites this paper
• Effectiveness and Safety of a Therapeutic Vaccine Against Angiotensin II Receptor Type 1 in Hypertensive Animals

  2013cites this paper
• Burnier et al Drug Adherence in Resistant Hypertension 219 Nonadherence : A Topic Burdened by Poor Methods and Many Misconceptions

  2013cites this paper
• Measuring, analyzing, and managing drug adherence in resistant hypertension.

  2013cites this paper
• South Asian Herbal Plants as Anti-hypertensive Agents- A Review

  2013cites this paper
• Vaccines Against Drug Abuse

  2012cites this paper
• Vaccination against high blood pressure.

  2012cites this paper
• An Interesting Vaccine

  2012cites this paper
• Inflammation in the pathophysiology of essential hypertension.

  2011cites this paper
• The More Complex Renin-Angiotensin System: New Insights Into An Old System

  2011cites this paper
• Stroke and the immune system: from pathophysiology to new therapeutic strategies.

  2011cites this paper
• Emerging drugs which target the renin–angiotensin–aldosterone system

  2011cites this paper
• Novel therapeutic strategies targeting vascular endothelium in essential hypertension

  2010cites this paper
• Review: Update on Newer Antihypertensive Medicines and Interventions

  2010cites this paper
• [New modalities of renin-angiotensin system inhibition: Renin inhibitors and active immunization against angiotensin II].

  2010cites this paper
• Avaliação estrutural e quantificação de colágeno na porção atrial do coração de cães sadios e diabéticos

  2009cites this paper
• resistant Hypertension : clinical considerations and the Potential for renal denervation

  year unknowncites this paper
• 2 Hypertension August 2013 Nonadherence : A Topic Burdened by Poor Methods and Many Misconceptions

  year unknowncites this paper